Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
| ▸ | CD74 | P04233 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674240 | 0.78 | P2RX7 (0.41) | — | |
| SCHEMBL32674412 | 0.78 | HPGD (0.39) | L3MBTL1NPC1 | |
| SCHEMBL32674398 | 0.73 | DDB1 (0.50) | DDB1CRBNNOTUML3MBTL1CA12 | |
| SCHEMBL32674279 | 0.72 | CYP19A1 (0.46) | PTGS2NPC1 | |
| SCHEMBL32674513 | 0.70 | RAB9A (0.46) | L3MBTL1NPC1 | |
| SCHEMBL32674471 | 0.70 | PTGS2 (0.41) | NOTUMMAOAL3MBTL1CA12CA9 | |
| SCHEMBL16631690 | 0.68 | L3MBTL1 (0.47) | DDB1CRBNNOTUMMAOAL3MBTL1 | |
| SCHEMBL32674293 | 0.67 | MCL1 (0.46) | — | |
| SCHEMBL32674491 | 0.67 | MCL1 (0.42) | — | |
| SCHEMBL32674477 | 0.66 | MCL1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | DDB1 4032/4885CRBN 2191/4885NOTUM 233/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | DDB1 4568/4885CRBN 626/4885NOTUM 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.